HealthTree Logo HealthTree Foundation
Donate

Notifications

You're all caught up

HealthTree Logo
Donate
Personal Health Record
  • My Feed
  • Recently viewed

Learn

  • Topics
  • Events

Explore

  • Find treatments & trials
  • Participate in research
  • Find a coach
  • Find a specialist
  • Talk to a patient navigator
  • Get involved
  • For researchers
  • For healthcare providers
  • About us
  • Get involved
  • For researchers
  • For healthcare providers
  • About us

Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Learn more about HealthTree
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Video

BETA - How do CELMoDs compare to IMiDS?

Posted by
HealthTree Logo HealthTree
• June 29, 2026

Description

How do CELMoDs compare to IMiDS?

On this video

Healthtree contact Omar Nadeem, MD, Specialist

Omar Nadeem, MD, Specialist

Dana Farber Cancer Institute

Healthtree contact Gayathri Ravi, Specialist

Gayathri Ravi, Specialist

The Kirklin Clinic at UAB Hospital

Related Content

  • Video All-Oral Myeloma Combo: Mezigdomide + Tazemetostat or Trametinib | Paul Richardson, MD | EHA 2025
  • Video Promising Result from a Novel Mezigdomide Combination Trial | Fredrik Schjesvold, MD, PhD | #EHA2025
  • Video Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24
  • Video Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24
  • Video New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates